Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy
Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral t...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2001-09, Vol.19 (18), p.3848-3851 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3851 |
|---|---|
| container_issue | 18 |
| container_start_page | 3848 |
| container_title | Journal of clinical oncology |
| container_volume | 19 |
| creator | HOLKOVA, Beata TAKESHITA, Kenichi CHENG, Debbie M VOLM, Matthew WASSERHEIT, Carolyn DEMOPOULOS, Rita CHANAN-KHAN, Asher |
| description | Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P =.0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P |
| doi_str_mv | 10.1200/JCO.2001.19.18.3848 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71175740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71175740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-3c658f312954c63d0da16eef849fd066c46074469ba5b1e8c036b0440a5802eb3</originalsourceid><addsrcrecordid>eNpNkctu1DAUhi1ERYfCEyAhb4BVgh1f4iyjodCb1EozCHaW4zjEVRIPtjNodjwDO16PJ6mnM1JZHcn6_v_I5wPgDUY5LhD6eLW8zdPEOa5yLHIiqHgGFpgVZVaWjD0HC1SSIsOCfD8FL0O4TywVhL0ApxgzVpVFsQB_zrvO6AhdBy_sj37YwVpHuzWwnqL1Jnq3tV4NcN0brzY76Ca4mv3WbtObneCditZMMcBvNvawvvy0yuoQnLYqmhbezcPoJuV38FptXLD_fv8NcKW8dqOCa28eocfksjeji4cdr8BJp4ZgXh_nGfj6-Xy9vMhubr9cLuubTBNOYkY0Z6IjuKgY1Zy0qFWYG9MJWnUt4lxTjkpKedUo1mAjNCK8QZQixQQqTEPOwPtD78a7n7MJUY42aDMMajJuDrLEuGQlRQkkB1B7F4I3ndx4O6ZvSYzkXoVMKuRehcSVxELuVaTU22P93Iymfcocb5-Ad0dABa2GzqtJ2_DEUYw4q3jiPhy4Pgn6laTIMKphSLWFvNfuv5UPaFehQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71175740</pqid></control><display><type>article</type><title>Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HOLKOVA, Beata ; TAKESHITA, Kenichi ; CHENG, Debbie M ; VOLM, Matthew ; WASSERHEIT, Carolyn ; DEMOPOULOS, Rita ; CHANAN-KHAN, Asher</creator><creatorcontrib>HOLKOVA, Beata ; TAKESHITA, Kenichi ; CHENG, Debbie M ; VOLM, Matthew ; WASSERHEIT, Carolyn ; DEMOPOULOS, Rita ; CHANAN-KHAN, Asher</creatorcontrib><description>Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P =.0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P <.0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).
In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2001.19.18.3848</identifier><identifier>PMID: 11559722</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Acquired Immunodeficiency Syndrome - complications ; Adult ; Antineoplastic agents ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; Chemotherapy ; Ethnic Groups ; Humans ; Lung Neoplasms - complications ; Lung Neoplasms - drug therapy ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Pharmacology. Drug treatments ; Registries ; Retrospective Studies ; Sarcoma, Kaposi - complications ; Sarcoma, Kaposi - drug therapy ; Survival Analysis ; Treatment Outcome</subject><ispartof>Journal of clinical oncology, 2001-09, Vol.19 (18), p.3848-3851</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-3c658f312954c63d0da16eef849fd066c46074469ba5b1e8c036b0440a5802eb3</citedby><cites>FETCH-LOGICAL-c363t-3c658f312954c63d0da16eef849fd066c46074469ba5b1e8c036b0440a5802eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14106596$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11559722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOLKOVA, Beata</creatorcontrib><creatorcontrib>TAKESHITA, Kenichi</creatorcontrib><creatorcontrib>CHENG, Debbie M</creatorcontrib><creatorcontrib>VOLM, Matthew</creatorcontrib><creatorcontrib>WASSERHEIT, Carolyn</creatorcontrib><creatorcontrib>DEMOPOULOS, Rita</creatorcontrib><creatorcontrib>CHANAN-KHAN, Asher</creatorcontrib><title>Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P =.0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P <.0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).
In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.</description><subject>Acquired Immunodeficiency Syndrome - complications</subject><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Ethnic Groups</subject><subject>Humans</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Sarcoma, Kaposi - complications</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkctu1DAUhi1ERYfCEyAhb4BVgh1f4iyjodCb1EozCHaW4zjEVRIPtjNodjwDO16PJ6mnM1JZHcn6_v_I5wPgDUY5LhD6eLW8zdPEOa5yLHIiqHgGFpgVZVaWjD0HC1SSIsOCfD8FL0O4TywVhL0ApxgzVpVFsQB_zrvO6AhdBy_sj37YwVpHuzWwnqL1Jnq3tV4NcN0brzY76Ca4mv3WbtObneCditZMMcBvNvawvvy0yuoQnLYqmhbezcPoJuV38FptXLD_fv8NcKW8dqOCa28eocfksjeji4cdr8BJp4ZgXh_nGfj6-Xy9vMhubr9cLuubTBNOYkY0Z6IjuKgY1Zy0qFWYG9MJWnUt4lxTjkpKedUo1mAjNCK8QZQixQQqTEPOwPtD78a7n7MJUY42aDMMajJuDrLEuGQlRQkkB1B7F4I3ndx4O6ZvSYzkXoVMKuRehcSVxELuVaTU22P93Iymfcocb5-Ad0dABa2GzqtJ2_DEUYw4q3jiPhy4Pgn6laTIMKphSLWFvNfuv5UPaFehQA</recordid><startdate>20010915</startdate><enddate>20010915</enddate><creator>HOLKOVA, Beata</creator><creator>TAKESHITA, Kenichi</creator><creator>CHENG, Debbie M</creator><creator>VOLM, Matthew</creator><creator>WASSERHEIT, Carolyn</creator><creator>DEMOPOULOS, Rita</creator><creator>CHANAN-KHAN, Asher</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010915</creationdate><title>Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy</title><author>HOLKOVA, Beata ; TAKESHITA, Kenichi ; CHENG, Debbie M ; VOLM, Matthew ; WASSERHEIT, Carolyn ; DEMOPOULOS, Rita ; CHANAN-KHAN, Asher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-3c658f312954c63d0da16eef849fd066c46074469ba5b1e8c036b0440a5802eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acquired Immunodeficiency Syndrome - complications</topic><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Ethnic Groups</topic><topic>Humans</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Sarcoma, Kaposi - complications</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOLKOVA, Beata</creatorcontrib><creatorcontrib>TAKESHITA, Kenichi</creatorcontrib><creatorcontrib>CHENG, Debbie M</creatorcontrib><creatorcontrib>VOLM, Matthew</creatorcontrib><creatorcontrib>WASSERHEIT, Carolyn</creatorcontrib><creatorcontrib>DEMOPOULOS, Rita</creatorcontrib><creatorcontrib>CHANAN-KHAN, Asher</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOLKOVA, Beata</au><au>TAKESHITA, Kenichi</au><au>CHENG, Debbie M</au><au>VOLM, Matthew</au><au>WASSERHEIT, Carolyn</au><au>DEMOPOULOS, Rita</au><au>CHANAN-KHAN, Asher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2001-09-15</date><risdate>2001</risdate><volume>19</volume><issue>18</issue><spage>3848</spage><epage>3851</epage><pages>3848-3851</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P =.0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P <.0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).
In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>11559722</pmid><doi>10.1200/JCO.2001.19.18.3848</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2001-09, Vol.19 (18), p.3848-3851 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71175740 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Acquired Immunodeficiency Syndrome - complications Adult Antineoplastic agents Antiretroviral Therapy, Highly Active Biological and medical sciences Chemotherapy Ethnic Groups Humans Lung Neoplasms - complications Lung Neoplasms - drug therapy Medical sciences Middle Aged Multivariate Analysis Pharmacology. Drug treatments Registries Retrospective Studies Sarcoma, Kaposi - complications Sarcoma, Kaposi - drug therapy Survival Analysis Treatment Outcome |
| title | Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A56%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Highly%20Active%20Antiretroviral%20Therapy%20on%20Survival%20in%20Patients%20With%20AIDS-Associated%20Pulmonary%20Kaposi%E2%80%99s%20Sarcoma%20Treated%20With%20Chemotherapy&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=HOLKOVA,%20Beata&rft.date=2001-09-15&rft.volume=19&rft.issue=18&rft.spage=3848&rft.epage=3851&rft.pages=3848-3851&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2001.19.18.3848&rft_dat=%3Cproquest_cross%3E71175740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71175740&rft_id=info:pmid/11559722&rfr_iscdi=true |